Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Medical World News

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

Asthma

Atopic Dermatitis

Biosimilars

Breast Cancer

COPD

COVID-19

Cholangiocarcinoma

Chronic Kidney Disease

Colorectal Cancer

Dermatology

Diabetes

Digital Health

Employers

Epilepsy

Heart Failure

Hematology

Hemophilia

Immuno-Oncology

Infectious Disease

Inflammation

Leukemia and Lymphoma

Liver

Lung Cancer

Lupus

Major Depressive Disorder

Medicare

Multiple Myeloma

Myasthenia Gravis

Myelodysplastic Syndromes

Oncology

Ophthalmology

Parkinson Disease

Prostate Cancer

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Rare Disease

Reimbursement

Respiratory

Rheumatology

Skin Cancer

Sleep

Spinal Muscular Atrophy

Type 1 Diabetes

Vaccines

Women's Health

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

eNewsletter

Mary is the associate editorial director for The American Journal of Managed Care® (AJMC®), The Center for Biosimilars®, and Evidence-Based Oncology™. She joined AJMC® in 2013 and oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®.

She has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on 

Articles

New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.


Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOL

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

First steps include assembling equity data and reaching out to veterans’ advocacy groups.

Veterans Health Stakeholders Identify Priorities to Ensure Health Equity in Telehealth 

Rose is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an editor.

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

A new study estimates that prescription of standard-of-care non–small-cell lung cancer (NSCLC) therapies is lower than expected in Medicaid programs, with significant variation between states. 

Targeted Therapies for NSCLC May Be Underused in Medicaid Programs, Study Suggests

Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.

She has a BA in print journalism from Penn State University. You can connect with Jaime on 

With most previous studies on ocular myasthenia gravis stemming from investigations the neurology field, the present investigators came to their conclusion via neuro-ophthalmic analysis.


Ocular MG Should Be Considered in Patients With Ptosis, Diplopia, Says Study 

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

Institute for Value-Based Medicine

All Coverage

Event Coverage

Stakeholders

Academia

Health System

Payers

Providers

Topics

1rem

Matthew W. Reynolds, PhD, is Vice President, Real World Evidence, IQVIA

A vaccine isn’t the panacea many assume it will be. Even when it becomes available, the virus won’t go away. Real world evidence will be needed to guide decision making.

Combatting COVID-19 With Real-World Evidence